D
Daniel Pella
Researcher at University of Pavol Jozef Šafárik
Publications - 143
Citations - 15987
Daniel Pella is an academic researcher from University of Pavol Jozef Šafárik. The author has contributed to research in topics: Population & Metabolic syndrome. The author has an hindex of 31, co-authored 136 publications receiving 10740 citations. Previous affiliations of Daniel Pella include Iuliu Hațieganu University of Medicine and Pharmacy & Louis Pasteur University.
Papers
More filters
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
Journal ArticleDOI
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
Paul M. Ridker,Jean G. MacFadyen,Tom Thuren,Brendan M. Everett,Peter Libby,R J Glynn,Paul Ridker,Alberto J. Lorenzatti,Henry Krum,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Jacques Genest,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Wolfgang Koenig,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,John J.P. Kastelein,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Brendan Everett,Les Forgosh,Robert J. Glynn,Barry Harris,Monica Ligueros,Erin A. Bohula,Bindu Charmarthi,Susan Cheng,Sherry Chou,Jacqueline Danik,Graham McMahon,Bradley Maron,MingMing Ning,Benjamin Olenchock,Reena Pande,Todd Perlstein,Aruna D. Pradhan,Natalia Rost,Aneesh Singhal,Viviany Taqueti,Nancy Wei,Howard A. Burris,Angela Cioffi,Anne Marie Dalseg,Nilanjan Ghosh,Julie R. Gralow,Tina Mayer,Hope S. Rugo,Vance G. Fowler,Ajit P. Limaye,Sara Cosgrove,Donald Levine,Renato D. Lopes,John D. Scott,Robert Hilkert,Georgia Tamesby,Carolyn Mickel,Brian Manning,Julian Woelcke,Monique Tan,Sheryl Manfreda,Tom Ponce,Jane Kam,Ravinder Saini,Kehur Banker,Thomas Salko,Panjat Nandy,Ronda Tawfik,Greg O'Neil,Shobha Manne,Pravin Jirvankar,Shankar Lal,Deepak Nema,Jaison Jose,Rory Collins,Kent Bailey,Roger S. Blumenthal,Helen M. Colhoun,Bernard J. Gersh +113 more
TL;DR: The hypothesis-generating data suggest the possibility that anti-inflammatory therapy with canakinumab targeting the interleukin-1β innate immunity pathway could significantly reduce incident lung cancer and lung cancer mortality.
Journal ArticleDOI
Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial
Ram Singh,Gal Dubnov,Mohammad A. Niaz,Saraswati Ghosh,Reema Singh,Shanti S. Rastogi,Orly Manor,Daniel Pella,Elliot M. Berry +8 more
TL;DR: An Indo-Mediterranean diet that is rich in alpha-linolenic acid might be more effective in primary and secondary prevention of CAD than the conventional step I NCEP prudent diet.
Journal ArticleDOI
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Paul M. Ridker,Jean G. MacFadyen,Brendan M. Everett,Peter Libby,Tom Thuren,Robert J. Glynn,John J.P. Kastelein,Wolfgang Koenig,Jacques Genest,Alberto J. Lorenzatti,John Varigos,Peter Siostrzonek,Peter Sinnaeve,Francisco Antonio Helfenstein Fonseca,Jose C. Nicolau,Nina Gotcheva,Huo Yong,Miguel Urina-Triana,Davor Miličić,Renata Cifkova,Riina Vettus,Stephan D Anker,Athanasios J. Manolis,Fernando Wyss,Tamás Forster,Axel Sigurdsson,Prem Pais,Alessandro Fucili,Hisao Ogawa,Hiroaki Shimokawa,Irina Veze,Birute Petrauskiene,Leon Salvador,Jan H. Cornel,Tor Ole Klemsdal,Félix Medina,Andrzej Budaj,Luminita Vida-Simiti,Zhanna Kobalava,Petar Otasevic,Daniel Pella,Mitja Lainscak,Ki-Bae Seung,Patrick J. Commerford,Mikael Dellborg,Marc Y. Donath,Juey-Jen Hwang,Hakan Kultursay,Marcus Flather,Christie M. Ballantyne,Seth Bilazarian,William Chang,Cara East,Les Forgosh,Barry Harris,Monica Ligueros +55 more
TL;DR: The magnitude of hsCRP reduction following a single dose of canakinumab might provide a simple clinical method to identify individuals most likely to accrue the largest benefit from continued treatment, and suggest that lower is better for inflammation reduction with canakinUMab.